WO1999000671A2 - Method for identification of tumor antigens with autoantibodies in serum - Google Patents

Method for identification of tumor antigens with autoantibodies in serum Download PDF

Info

Publication number
WO1999000671A2
WO1999000671A2 PCT/US1998/013295 US9813295W WO9900671A2 WO 1999000671 A2 WO1999000671 A2 WO 1999000671A2 US 9813295 W US9813295 W US 9813295W WO 9900671 A2 WO9900671 A2 WO 9900671A2
Authority
WO
WIPO (PCT)
Prior art keywords
subject
proteins
autoantibodies
protein
cancer
Prior art date
Application number
PCT/US1998/013295
Other languages
French (fr)
Other versions
WO1999000671A3 (en
Inventor
Samir M. Hanash
David Misek
Robert Hinderer
Latha Prasanan
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21967731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999000671(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AT98932884T priority Critical patent/ATE266203T1/en
Priority to DE69823660T priority patent/DE69823660D1/en
Priority to JP54639598A priority patent/JP4065574B2/en
Priority to EP98932884A priority patent/EP0991945B2/en
Priority to CA002294514A priority patent/CA2294514C/en
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Priority to DK98932884T priority patent/DK0991945T4/en
Priority to AU82673/98A priority patent/AU8267398A/en
Publication of WO1999000671A2 publication Critical patent/WO1999000671A2/en
Publication of WO1999000671A3 publication Critical patent/WO1999000671A3/en
Priority to US09/464,840 priority patent/US6677128B1/en
Priority to US10/674,228 priority patent/US20040191841A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Definitions

  • the present invention relates to a method for identification of cellular protein antigens to which patients with cancer, or patients at risk for cancer, may develop autoantibodies.
  • the method of the invention involves the use of patient derived sera for the identification of the cellular protein antigens using two- dimensional gel electrophoresis followed by Western Blot analysis.
  • the identification of such protein antigens provides novel markers that can be utilized for screening, for diagnostics and prognosis of disease.
  • the invention also provides for the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens in sera from individuals that may harbor such antibodies.
  • the invention further relates to the use of the identified antigens as immunogens for stimulation of an immune response in patients expressing such protein antigens.
  • the invention is demonstrated by way of example in which elevated levels of circulating autoantibodies reactive against a tumor specific antigen were identified in sera derived from a lung cancer patient. In addition, elevated levels of circulating autoantibodies reactive against several specific ⁇ -tubulin isoforms were detected in the sera of neuroblastoma patients.
  • PCNA protein-binding protein
  • candidate proteins are singled out and investigated with respect to their ability to induce antibodies in patients, as was investigated for p53 (Crawford, L.V., Firm, D.C., Bulbrook, R.D., 1984, Int J Cancer 30:403-408).
  • SEREX a technique called SEREX relies on serological analysis of recombinant cDNA expression libraries to identify tumor antigens (Old, L., et al. 1998, J. Exp. Med. 187: 1 163-1167).
  • SEREX electrophoresis methods
  • two dimensional or “2D”-electrophoresis has been widely utilized to separate proteins in complex mixtures such as tissues or body fluids.
  • the first electrophoresis step generally separates proteins based on their charge.
  • the second electrophoresis step generally separates proteins based on their molecular weight.
  • the use of high resolution two-dimensional electrophoresis allows the simultaneous separation of up to several thousand individual proteins, providing an overall protein map of the protein mixture analyzed.
  • the separated proteins can be visualized in the gel by means of staining with a variety of staining compounds including Coomassie blue or silver.
  • mixtures containing isotopically labeled proteins such as with 25 S methionine, can be visualized by means of autoradiography.
  • the identification of such protein antigens provides novel markers that can be used for screening, diagnostics and prognosis of disease.
  • the invention comprises separating antigen-containing protein mixtures by two-dimensional gel electrophoresis followed by transfer of the separated proteins onto a membrane. Specific antigens in the protein mixture are detected by treatment of the membrane with a patient's sera followed by detection of specifically bound antibody by use of a second labeled antibody which specifically binds the first antibody.
  • Separated protein antigens are considered disease specific antigens if they show prominence in the presence of sera suspected of harboring autoantibodies compared to control sera.
  • the source of proteins for two-dimensional analysis includes unfractionated tumors, isolated cancer cells or tumor infiltrating cells or cultured cell lines or subcellular protein fractions such as secreted proteins, membrane proteins, cytosolic or nuclear proteins.
  • the present invention also relates to the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens. Such immunoassays can be utilized for screening, for diagnostics and prognosis of disease.
  • measurement of antibody levels in a patient's sample can be used for the early diagnosis of diseases such as cancer.
  • the monitoring of serum antibody levels can be used prognostically to stage progression of the disease.
  • the present invention further relates to the use of the identified protein antigens as immunogens for stimulation of an host immune response against the tumor cells. It is expected that such an approach can be used as a method for inhibiting tumor cell growth or facilitating tumor cell killing in individuals with specific cancers.
  • circulating autoantibodies reactive against specific ⁇ -tubulin isoforms, and their cleavage products, were detected in the sera of patients with neuroblastoma.
  • the finding that ⁇ -tubulin isoforms are immunogenic in neuroblastoma patients provides a basis for development of diagnostic methods for neuroblastoma and other cancers in which these ⁇ -tubulin isoforms are expressed, as well as a means for monitoring prognosis of various therapeutic treatments for the disease.
  • the discovery that specific ⁇ -tubulin isoforms are expressed in tumor cells provides a method for use of specific ⁇ -tubulin isoforms as immunogens for stimulation of an immune response against the tumor cells.
  • Figure IB A normal lung treated with serum from a patient with lung adenocarcinoma.
  • FIG. 1 Western blot of a two-dimensional gel separation of a primary neuroblastoma SY5Y lysate treated with the serum from a newly diagnosed patient with neuroblastoma.
  • An aliquot of SY5Y proteins was solubilized in a urea cocktail and 40 micrograms of solubilized protein was loaded onto a carrier ampholyte base (pH 3.8) tube gel and separated in the first dimension for 12, 000 volt hours.
  • the first- dimension tube gel was loaded onto a cassette containing the second dimension gel, after an equilibration step. Electrophoresis in the second dimension was performed until the tracking dye present in the equilibration buffer reached the opposite end of the second dimension gel, in relation to the first dimension gel.
  • PVDF polyvinylideme flouride
  • the membrane was preincubated with a blocking buffer and subsequently incubated with serum obtained from the same patient with neuroblastoma whose tumor was analyzed.
  • the serum was utilized at a dilution of 1 : 100, for 1 hr at room temperature. After three washes with a buffer solution, the membrane was incubated for 1 hr with a rabbit anti-human IgG antibody. Reactive proteins were revealed with luminol.
  • a set of coalesced protein spots labeled as LP1 was identified as containing ⁇ -tubulin isoforms for which an antibody was present in the patient's serum. This set was not detectable in a similar blot which was incubated with the serum of patients with other types of cancer or with the serum of normal individuals.
  • FIG. 3 Western blot of two-dimensional gel separation of neuroblastoma protein lysate treated with the serum of a newly diagnosed patient with Wilms tumor. The conditions for the Western blot are as described in Figure 2. There is a lack of reactivity in the region of LP1.
  • FIG. 4 Western blot of two-dimensional gel separation of SY5Y protein lysate treated with the serum of a newly diagnosed patient with neuroblastoma.
  • the conditions for the Western Blot are as described in Figure 2 with the exception that the membranes were incubated for 1 hr with a rabbit anti-human IgM antibody. Reactive proteins were revealed with luminol. A set of lower molecular weight proteins indicated as Tl, T2 and T3 were identified as containing ⁇ - tubulin isoforms. This set was not detectable in a similar blot which was incubated with control sera.
  • Figure 5. Western blot of SY5Y proteins treated with a monoclonal antibody that reacts with ⁇ -tubulin BI and BII. Reactive spots are identified as LP1 , and T1-T3.
  • FIG. 1 Western blot of Sy5Y proteins treated with a monoclonal antibody that reacts with tubulin Bill. Reactive spots are identified as LP1, and TITS.
  • Figure 7. Coomassie Blue stained blot of Sy5Y proteins. Similar blots were used to cut out LP1 spots for amino acid sequencing.
  • the present invention achieves a highly desirable objective, namely the identification of novel protein antigens for which individuals with, or at risk for different types of cancer, carry autoantibodies against tumor cell protein antigens.
  • protein antigens can in turn be purified and utilized to screen a patient's serum for the presence of circulating antibodies to such antigens, by means of sensitive and rapid immunoadsorbent assays or by other procedures.
  • the invention also relates to using the novel protein antigens to immunize patients suffering from diseases characterized by the expression of the identified protein antigens.
  • Stimulation of an immunological response to such antigens is intended to elicit a more effective attack of tumor cells; such as inter alia inhibiting tumor cell growth or facilitating the killing of tumor cells.
  • the method for identifying novel protein antigens, to which a subject with cancer produces autoantibodies comprises the following steps:
  • a wide variety of protein mixtures that may contain antigens against which autoantibodies are present in serum can be prepared and separated into individual proteins by means of two-dimensional electrophoresis.
  • Whole cell extracts or body fluids can be analyzed for proteins which have elicited autoantibodies.
  • subsets of proteins such as secreted proteins, nuclear proteins or membrane proteins can be subjected to two-dimensional electrophoresis and analyzed separately for proteins which have elicited autoantibodies so as to increase the abundance of such proteins in the mixture.
  • Preparative loads consisting of several milligrams of proteins in a mixture can also be applied to electrophoretic gels to increase the amounts of proteins which have elicited autoantibodies.
  • the particular advantage of the present invention is that no prior knowledge concerning the nature of the antigen is necessary. Autoantibodies to multiple antigens can be detected simultaneously through the use of a two- dimensional separation procedure. Additionally, the pattern of reactivity of a serum with a particular set of proteins in the two dimensional gel patterns, may be diagnostic of a particular cancer or indicative of a risk for a particular cancer.
  • the present invention is based on the discovery that serum from an individual that contains autoantibodies, such as a patient with cancer of the lung or neuroblastoma, can be used to identity protein antigens expressed in cells of a particular tissue, such as for example, cells of a tumor, or in a representative cell type, to which the patient has autoantibodies.
  • serum from neuroblastoma patients contained antibodies which were immunospecific for ⁇ - tubulin isoforms.
  • the present invention provides a method for identifying cellular protein antigens to which patients with cancer may develop autoantibodies.
  • the method is validated by the use of serum from individuals with cancer and from controls, without cancer.
  • a body fluid which may contain autoantibodies, such as serum is obtained from a patient known to have a particular cancer.
  • a similar body fluid containing antibodies is obtained from a control subject that does not have cancer.
  • tumor tissue as well as normal tissue to be used as a control is obtained.
  • tumor tissues from other patients with the same disease and control tissues from other normal controls can be utilized. It is also not necessary to utilize primary tissues; cells grown in culture may provide appropriate substitutes for tumor tissues or controls.
  • protein subsets from such tissues or such cells in culture may be prepared. Such subsets may include secreted proteins, nuclear proteins, membrane proteins or other subcellular fractions.
  • Electrophoresis in the first dimension generally separates proteins based on charge
  • electrophoresis in the second dimension referred to as SDS PAGE
  • tissue Prior to two-dimensional gel electrophoresis, aliquots of whole tissues, or cells are solubilized using any one of a variety of solubilization cocktails known to those of skill in the art.
  • tissue can be solubilized by addition of lysis buffer consisting of (per liter) 8 M urea, 20 ml of Nonidet P-40 surfactant, 20 ml of ampholytes (pH 3.5-10), 20 ml of 2-mercaptoethanol, and 0.2 mM of phenylmethylsulfonyl fluoride (PMSF) in distilled deionized water.
  • lysis buffer consisting of (per liter) 8 M urea, 20 ml of Nonidet P-40 surfactant, 20 ml of ampholytes (pH 3.5-10), 20 ml of 2-mercaptoethanol, and 0.2 mM of phenylmethylsulfonyl fluoride (PMSF) in distilled deionized water.
  • PMSF phen
  • isoelectric focusing is sensitive to charge modification, it is important to minimize protein alterations (e.g., proteolysis, deamidation of glutamine and asparagine, oxidation of cystine to cystic acid, carbamylation) that can result from improper sample preparation.
  • proteins alterations e.g., proteolysis, deamidation of glutamine and asparagine, oxidation of cystine to cystic acid, carbamylation
  • samples should be stored frozen at -80°C for short periods ( ⁇ 1 month) to limit significant protein modification. Approximately 30 ⁇ l aliquots containing 70 ug of protein may be loaded on individual gels. Prepared protein samples are loaded onto electrophoretic gels for isoelectric focusing separation in the first dimension which separates proteins based on charge.
  • a number of first dimension gel preparations may be utilized including tube gels for carrier ampholyte-based separations, or gel strips for immobilized gradient based separations. After first dimension separation, proteins are transferred onto the second dimension gel, following an equilibration procedure and separated using SDS PAGE which separates proteins based on molecular weight. Multiple gels can be prepared from individual samples. Methods of two dimensional electrophoresis are known to those skilled in the art. For example, carrier ampholyte based two dimensional gel electrophoresis can be done as previously described (Strahier et al, Journal of Clinical Investigtion, 85:200-207, 1990). In most cases aliquots are immediately applied onto isoelectric focusing gels (IEF).
  • IEF isoelectric focusing gels
  • First-dimension gels contain 50 ml of ampholytes per liter (pH 3.5-10). Generally, isoelectric focusing is done at 1,200 V for 10 h and 1,500 V for the last 2 h. 20 gels are generally run simultaneously.
  • an acrylamide gradient of 1 1.4-14.0 g/ml can be used.
  • protein spots in gels may be visualized by the silver-staining technique of Merril et al. (Merril et al, Science, 211 :1437-1438, 1961).
  • immobilized pH gradient (IPG) two dimensional gels may be used (Hanash S. M., et al., 1991 , Proc. Natl. Acad.
  • Samples are prepared using lysis buffer as discussed above.
  • an immobilized pH gradient covering the separation range of pH 4-10 is used.
  • the second dimension is the same as for the carrier ampholyte gels described above.
  • IPG gels are prepared using derivatives of acrylamide having carboxyl or tertiary amino groups with specific pK values.
  • a linear pH gradient is prepared from a dense, acidic solution and a light, basic solution using a two-chamber microgradient former. The pH gradient is stabilized during polymerization of the Immobiline acrylamide-bisacrylamide matrix by a co-linear gradient of glycerol.
  • the second dimension separates proteins on the basis of molecular weight in an SDS gel.
  • An 11.5 to 14% (2.6% cross-linking) acrylamide gradient provides effective separation of proteins having a mass of from 10,000 to 100,000 Da. Proteins outside this range may be less well resolved. Proteins with molecular weight less than 10,000 Da electrophorese close to the dye front and are less well resolved.
  • proteins are transferred from the two dimensional gels onto membranes commonly used for Western blotting.
  • the techniques of Western blotting and subsequent visualization of proteins are also well known in the art (Sambrook et al, "Molecular Cloning, A Laboratory Manual", 2 nd Edition, Volume 3, 1989, Cold Spring Harbor).
  • the standard procedures may be used, or the procedures may be modified as known in the art for identification of proteins of particular types, such as highly basic or acidic, or lipid soluble, etc. (See for example, Ausubel, et al., 1989, Current Protocols in Molecular Biology, Green
  • the patient and control sera are diluted to various concentrations, e.g., one volume of serum to 100 volumes of buffer, prior to being utilized in an incubation step, as in the procedure of Western blot analysis. Non-specific binding may be minimized by preclearing the serum prior to the incubation step.
  • a second antibody specific for the first antibody is utilized in the procedure of Western blot analysis to visualize proteins that reacted with the first antibody.
  • spots As a result of nonspecific reactivity with antibodies in the serum. Spots corresponding to proteins that have elicited specific autoantibodies are distinguishable from nonspecific spots based on their presence in Western Blots prepared with patients' sera compared to control sera, and/or the presence of a spot in the disease tissues or cell lines or extracts compared to control tissues, cell lines or extracts.
  • the protein spots, in two dimensional gels of the same protein source used for Western blots are visualized using a staining procedure or by autoradiography. Spots in the gels that match the spots of interest in Western blots are identified by means of an overlay or a matching procedure between the gels and the blots. Once the spots that contain proteins that may have elicited autoantibodies are identified in two-dimensional gels, the protein can be extracted from the two- dimensional gels and utilized for a structural characterization and/or for making antibodies against such protein.
  • the amino acid sequence of the protein can be derived by direct sequencing with an automated amino acid sequencer.
  • a protein of interest may be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any standard technique for purification of proteins.
  • chromatography e.g., ion exchange, affinity, and sizing column chromatography
  • centrifugation e.g., centrifugation
  • differential solubility e.g., differential solubility
  • purified protein can be used in immunoassays designed to detect the presence of autoantibodies in a subject's serum, or alternatively, such protein preparations may be used for immunization as described infra.
  • the present invention is demonstrated by way of example wherein elevated levels of circulating autoantibodies reactive against several specific ⁇ -tubulin isoforms and their cleavage products were detected in the sera of neuroblastoma patients.
  • the detection and/or quantitative measurement of ⁇ -tubulin isoforms or their cleavage products in serum or other body fluids can be used in screening of subjects who are at risk for neuroblastoma or other disorders in which ⁇ -tubulin isoforms are expressed. Additionally, autoantibodies to the specific ⁇ -tubulin isoforms were not detected in neuroblastoma patients being treated, or in remission from the disease, indicating that measurement of autoantibodies can be used prognostically to stage the progression of the disease. Thus, the specific subtypes of tubulin autoantibodies may have diagnostic, prognostic, or therapeutic significance.
  • measurement of autoantibodies reactive against an identified tumor specific protein antigen can be used for the early diagnosis of diseases such as cancer.
  • the monitoring of autoantibody levels can be used prognostically to stage the progression of the disease.
  • the detection of autoantibodies in a sample from a patient can be accomplished by any of a number of methods.
  • Such methods include immunoassays which include but are not limited to competitive and non-competitive assay systems using techniques such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.
  • immunoassays include but are not limited to competitive and non-competitive assay systems using techniques such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement fixation
  • Such an immunoassay is carried out by a method comprising contacting a serum sample derived from a subject with a sample containing the protein antigen under conditions such that specific antigen-antibody binding can occur, and detecting or measuring the amount of any immunospecific binding by the autoantibody.
  • a serum sample derived from a subject with a sample containing the protein antigen under conditions such that specific antigen-antibody binding can occur, and detecting or measuring the amount of any immunospecific binding by the autoantibody.
  • tissue sections for example, can be used to detect the presence of autoantibody wherein the detection of autoantibody is an indication of a diseased condition.
  • the levels of autoantibodies in a sample are compared to the levels present in an analogous sample from a portion of the body or from a subject not having the disorder.
  • the immunoassays of the invention are not limited to those designed for detection of autoantibodies in a subject's serum, but also include, immunoassays for detecting expression of the identified protein antigens in a subject's sample.
  • purified protein antigen can be used to produce antibodies that can be used in accordance with the invention.
  • the protein antigens identified by the method of the invention can be prepared in preparative gels, eluted from the gels, and used as immunogens for the production of antibodies which immunospecifically bind such an immunogen.
  • the antibodies are made by methods known to those skilled in the art. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.
  • Antibodies can be used in assays, such as the immunoassays listed above, to detect, prognose, diagnose, or monitor cancer in an individual, or monitor the treatment thereof.
  • an immunoassay is carried out by a method comprising contacting a sample derived from a subject with an antibody under conditions such that immunospecific binding can occur, and detecting or measuring the amount of any immunospecific binding by the antibody
  • reagents other than antibodies such as, for example, nucleic acid molecules, polypeptides or chemical compounds that specifically bind to ⁇ -tubuhn isoforms, can be used m assays to detect the expression of ⁇ -tubulm isoforms
  • such binding of antibody by tissue sections can be used to detect expression of the protein wherein the expression of the protein is an indication of a diseased condition
  • the levels of expressed proteins are compared to levels relative to that present in an analogous sample from a portion of the body oi from a subject not having the disorder
  • the identification of autoantibodies to novel protein antigens associated with particular cancers provides a basis for immunotherapy of the disease
  • the patient may be immunized with the protein antigens to elicit an immune response which facilitates killing of tumor cells or inhibiting tumor cell growth
  • the protein antigens can be prepared using the methods described above for purification of proteins
  • an immunogen comprising a purified protein antigen to which a patient cancer has developed autoantibodies, is used to elicit an immune response
  • the protein antigen may be formulated with a suitable adjuvant in order to enhance the immunological response to the protein antigen
  • suitable adjuvants include, but are not limited to mineral gels, e g aluminum hydroxide, surface active substances such as lysolecithm, pluromc polyols, polyamons, peptides, oil emulsions, and potentially useful human adjuvants such as BCG (bacilli Calmett-Guerin) and (Corynebacterium parvum)
  • BCG Bacilli Calmett-Guerin
  • Corynebacterium parvum Many methods may be used to introduce the formulations derived above, including but not limited to oral, mtradermal, intramuscular, mtrape ⁇ toneal, intravenous, and subutaneous
  • ⁇ -tubulin III differs from other forms of tubulin by a short sequence at the C-terminal end.
  • peptides encompassing this sequence may be utilized as an immunogen to elicit antibodies specifically reactive to against tumors that express ⁇ -tubulin III.
  • the method of the present invention was applied to patients with lung cancer for identification of tumor specific antigens.
  • One such experiment is described below.
  • An aliquot of a lung adenocarcinoma tumor was solubilized in a urea cocktail, as described above, and 40 micrograms of solubilized protein was loaded onto a carrier ampholyte based (pH 3-8) tube gel and subjected to isoelectric focusing in the first dimension for 12,000 volt hours (700V x 16h and 1000V x 2h).
  • the first- dimension tube gel was loaded onto a cassette containing the second dimension gel, after an equilibration step.
  • Electrophoresis in the second dimension using SDS PAGE was done until the tracking dye present in the equilibration buffer reached the opposite end of the second dimension gel, in relation to the first dimension gel. Following electrophoresis the separated proteins were transferred onto a nitrocellulose membrane. The membrane was preincubated with a blocking buffer and subsequently incubated with serum obtained from a patient with lung adenocarcinoma at a dilution of 1/100 (diluted in Tris-buffered-saline (TBS) ;0.01% Tween 20; 1.8 gm/100 ml nonfat dry milk), for 1 hr at room temperature.
  • TBS Tris-buffered-saline
  • the membrane was incubated for 1 hr with a sheep anti-human antibody (available from Amersham). Reactive proteins were revealed with luminol.
  • a candidate protein in the tumor for which an antibody was present in the patient's serum is shown in Figure 1A.
  • Figure IB the protein spot was not detectable in a blot of normal lung proteins which was incubated with the patient's serum.
  • sera from subjects with neuroblastoma were screened for reactivity against tumor proteins.
  • the sera samples from the neuroblastoma patients were found to be reactive against a set of neuroblastoma specific proteins identified as ⁇ -tubulin isoforms and their cleavage products.
  • MATERIALS AND METHODS Sera were obtained from patients with neuroblastoma as well as from patients with other tumor types including cancer of the lung, esophagus, sarcomas and Wilms tumors.
  • Different Western blots were prepared using the different tumors or the neuroblastoma cell line SY5Y as sources for solubilized proteins.
  • An aliquot of SY5Y proteins was solubilized in a urea cocktail as described above and 40 micrograms of solubilized protein was loaded onto a carrier ampholyted base (pH 3.8) tube gel and separated by isoelectric focusing in the first dimension for 12, 000 volt hours (700V x 16 h followed by 1000V x 2 h) .
  • the first-dimension tube gel was loaded onto a cassette containing the second dimension gel, after an equilibration step. Electrophoresis in the second dimension using SDS PAGE was done until the tracking dye present in the equilibration buffer reached the opposite end of the second dimension gel, in relation to the first dimension gel. Following electrophoresis the separated proteins were transferred on to a polyvinylideme flouride (PVDF) membrane (Millipore). The membrane was preincubated with a blocking buffer and subsequently incubated with serum obtained from the same patient with neuroblastoma whose tumor was being analyzed.
  • PVDF polyvinylideme flouride
  • the serum which was diluted 1 :100 in the buffer solution (Tris-buffered-saline containing .01% Tween20 and 1.8 gm/100 ml non-fat dry milk), was incubated with the filter for 1 hr at room temperature. After three washes with the buffer solution, the membrane was incubated for 1 hr with a rabbit anti-human IgG antibody (available from Amersham). Reactive proteins were revealed with luminol. A set of coalesced protein spots labeled LPl, were identified as containing ⁇ -tubulin isoforms for which an autoantibody was present in the patient's serum.
  • the buffer solution Tris-buffered-saline containing .01% Tween20 and 1.8 gm/100 ml non-fat dry milk
  • the spots designated LPl a to LPld in Figure 7 were excised and the amino terminal sequence of each protein was determined.
  • the amino acid sequences were as follows: I. LPla major- MREIVHIQAGQCGNQI (SEQ ID NOT) minor- EEGCVSLQVGQAGVQI (SEQ ID NO:5)
  • TBBl tubulin isoform TBBl or TBB3
  • TBB2 or TBB5 tubulin isoform TBBl or TBB5
  • TBBl and TBB3 have the same N-terminus, but differ at C -terminus. There were some minor signals as well in some cycles.
  • TBB2 and TBB5 have L instead of I in position 7. There was some L observed in this cycle. However it may have come from an unrelated sequence along with the other minor residues.
  • the major sequence is of LPlb is that of tubulin isoform TBA1 and the minor sequence is that of tubulin isoform TBBl and/or TBB3.
  • LPlc The major sequence of LPlc is that of tubulin isoform TBBl and/or TBB3 with possibly some TBB5 and/or TBB2 tubulin isoforms present (Lin #7).
  • tubulin isoform TBBl and/or TBB3 The major sequence of LPld is tubulin isoform TBBl and/or TBB3 with a minor amount of TBAltubulin isoform detected.
  • ⁇ -tubulin isoforms types I and II and type III were found to be expressed at high level in neuroblastoma tumors and the SY5Y based on Western blot analysis of neuroblastoma tumor proteins separated by two dimensional gel electrophoresis, using isoform specific tubulin beta antibodies (Figure 5, 6).
  • tubulin beta isoforms types I and II and type III were found to be expressed at high level in neuroblastoma tumors based on Western blot analysis of neuroblastoma tumor and SY5Y proteins separated by two dimensional gel electrophoresis using isoform specific tubulin beta antibodies ( Figures 4, 5 and 6).
  • Antibody specificity was determined by means of comparisons of Western blots of different tumor types reacted with different neuroblastoma patient sera, with Western blots reacted with control sera.
  • Several immunoreactive spots that were found in Western blots of neuroblastoma tumors and a neuroblastoma cell line that were incubated with sera from neuroblastoma patients were absent in Western blots of other tumors or in neuroblastoma Western blots that were treated with control sera.
  • One set of neuroblastoma immunoreactive proteins was localized in two-dimensional separations of neuroblastoma proteins in which proteins were revealed by staining with silver or Coomassie Blue.
  • ⁇ -tubulin isoforms were found to be expressed at high level in neuroblastoma tumors based on Western blot analysis of neuroblastoma tumor proteins separated by two dimensional gel electrophoresis, which were reacted with isoform specific ⁇ -tubulin antibodies.
  • Another set of immunoreactive proteins were similarly identified as cleavage products of tubulin beta isoforms.
  • tubulin beta isoforms as immunogenic in cancer provides a basis for the development of diagnostic and screening tests for cancers in which these isoforms are expressed and for the development of novel tubulin based strategies for cancer therapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for identification of cellular protein antigens to which patients with cancer, or patients at risk for cancer, may develop autoantibodies. The method of the invention involves the use of patient derived sera for the identification of the cellular protein antigens using two-dimensional gel electrophoresis followed by Western Blot analysis. The identification of such protein antigens provides novel markers that can be utilized for screening, for diagnostics and prognosis of disease. The invention also provides for the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens in sera from individuals that may harbor such antibodies. The invention further relates to the use of the identified antigens as immunogens for stimulation of an immune response in patients expressing such protein antigens. The invention is demonstrated by way of example in which elevated levels of circulating autoantibodies reactive against a tumor specific antigen were identified in sera derived from a lung cancer patient. In addition, elevated levels of circulating autoantibodies reactive against several specific β-tubulin isoforms were detected in the sera of neuroblastoma patients.

Description

METHOD FOR IDENTIFICATION OF CELLULAR PROTETN
ANTIGENS AND PRESENCE OF ANTIBODIES TO SPECIFIC
CELLULAR PROTEIN ANTIGENS IN SERUM
1. INTRODUCTION
The present invention relates to a method for identification of cellular protein antigens to which patients with cancer, or patients at risk for cancer, may develop autoantibodies. The method of the invention involves the use of patient derived sera for the identification of the cellular protein antigens using two- dimensional gel electrophoresis followed by Western Blot analysis. The identification of such protein antigens provides novel markers that can be utilized for screening, for diagnostics and prognosis of disease. The invention also provides for the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens in sera from individuals that may harbor such antibodies. The invention further relates to the use of the identified antigens as immunogens for stimulation of an immune response in patients expressing such protein antigens. The invention is demonstrated by way of example in which elevated levels of circulating autoantibodies reactive against a tumor specific antigen were identified in sera derived from a lung cancer patient. In addition, elevated levels of circulating autoantibodies reactive against several specific β-tubulin isoforms were detected in the sera of neuroblastoma patients.
2. BACKGROUND OF THE INVENTION Autoantibodies to normal or abnormal cellular proteins are known to be produced by patients in certain diseases such as autoimmune diseases and cardiovascular-related disorders, in some cases even before the disease has produced overt symptoms. However, such autoantibodies have rarely, if ever, been observed in individuals with cancer. Such antibodies to tissue proteins, e.g. p53, may serve as early markers for different types of cancer or for other illnesses. Their detection or the detection of their corresponding antigens in serum or other tissues and body fluids may have utility as indicators of risk for particular types of cancer or for other diseases, as diagnostic markers or as prognostic indicators.
The detection of autoantibodies to cellular antigens and the identification of proteins that have elicited autoantibodies has been accomplished using a variety of approaches. For example, Proliferating Cell Nuclear Antigen
(PCNA) was first described as a nuclear antigen which bound antibodies from some patients with lupus erythematosus (Miyachi, K., Fritzler, M.J., and Tan, E.M., 1978, J. Immunol 121 :2228-2234). It was subsequently observed that resting lymphocytes did not react with the antibody, in contrast to mitogen stimulated lymphocytes which displayed nuclear staining. This ultimately led to the identification of the protein, designated PCNA which is recognized by this autoantibody in lupus (Tan, E.M., Ogata, K., and Takasaki, Y. 1987, J. Rheumatol., 13:89-96). In some other cases, candidate proteins are singled out and investigated with respect to their ability to induce antibodies in patients, as was investigated for p53 (Crawford, L.V., Firm, D.C., Bulbrook, R.D., 1984, Int J Cancer 30:403-408). In addition, a technique called SEREX relies on serological analysis of recombinant cDNA expression libraries to identify tumor antigens (Old, L., et al. 1998, J. Exp. Med. 187: 1 163-1167). Thus, many approaches have been followed to search for proteins against which autoantibodies may be produced. The combination of two different electrophoresis methods (so called
"two dimensional" or "2D"-electrophoresis) has been widely utilized to separate proteins in complex mixtures such as tissues or body fluids. The first electrophoresis step generally separates proteins based on their charge. The second electrophoresis step generally separates proteins based on their molecular weight. The use of high resolution two-dimensional electrophoresis allows the simultaneous separation of up to several thousand individual proteins, providing an overall protein map of the protein mixture analyzed. The separated proteins can be visualized in the gel by means of staining with a variety of staining compounds including Coomassie blue or silver. Alternatively, mixtures containing isotopically labeled proteins such as with 25S methionine, can be visualized by means of autoradiography. Methods have been developed for the identification of protein(s) that react with a specific antibody among a large number of proteins separated by two- dimensional electrophoresis. The technique of Western blotting can readily reveal the protein with which the antibody reacts if the protein is sufficiently abundant and the antibody is sufficiently specific and with a sufficiently high titer, i.e., high affinity and avidity. The use of whole sera that may contain unknown antibodies against unknown protein antigens present in tumors or precancerous lesions for Western blotting of two dimensional gels has not been reported. Such technology may theoretically be complicated by a large measure of nonspecific reactivity, making it difficult to interpret results. Thus, the methods of the present invention, using Western blotting of two-dimensional gel electrophoresis of complex protein mixtures for the identification of novel antigens for which autoantibodies are present in sera of patients with tumors or with precancerous lesions, is novel.
3. SUMMARY OF THE INVENTION It is an object of the present invention to provide a procedure for the identification of cellular protein antigens and for the detection of antibodies to specific cellular protein antigens in the serum of patients with cancer or with precancerous lesions. The identification of such protein antigens provides novel markers that can be used for screening, diagnostics and prognosis of disease. The invention comprises separating antigen-containing protein mixtures by two-dimensional gel electrophoresis followed by transfer of the separated proteins onto a membrane. Specific antigens in the protein mixture are detected by treatment of the membrane with a patient's sera followed by detection of specifically bound antibody by use of a second labeled antibody which specifically binds the first antibody. Separated protein antigens are considered disease specific antigens if they show prominence in the presence of sera suspected of harboring autoantibodies compared to control sera. The source of proteins for two-dimensional analysis includes unfractionated tumors, isolated cancer cells or tumor infiltrating cells or cultured cell lines or subcellular protein fractions such as secreted proteins, membrane proteins, cytosolic or nuclear proteins. The present invention also relates to the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens. Such immunoassays can be utilized for screening, for diagnostics and prognosis of disease. In accordance with the invention, measurement of antibody levels in a patient's sample can be used for the early diagnosis of diseases such as cancer. Moreover, the monitoring of serum antibody levels can be used prognostically to stage progression of the disease.
Additionally, the present invention further relates to the use of the identified protein antigens as immunogens for stimulation of an host immune response against the tumor cells. It is expected that such an approach can be used as a method for inhibiting tumor cell growth or facilitating tumor cell killing in individuals with specific cancers.
In a specific embodiment of the invention described herein, circulating autoantibodies reactive against specific β-tubulin isoforms, and their cleavage products, were detected in the sera of patients with neuroblastoma. The finding that β-tubulin isoforms are immunogenic in neuroblastoma patients provides a basis for development of diagnostic methods for neuroblastoma and other cancers in which these β-tubulin isoforms are expressed, as well as a means for monitoring prognosis of various therapeutic treatments for the disease. In addition, the discovery that specific β-tubulin isoforms are expressed in tumor cells provides a method for use of specific β-tubulin isoforms as immunogens for stimulation of an immune response against the tumor cells.
4. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1A. Western blots of a lung adenocarcinoma treated with a serum from a patient with lung adenocarcinoma tumor.
Figure IB. A normal lung treated with serum from a patient with lung adenocarcinoma.
Figure 2. Western blot of a two-dimensional gel separation of a primary neuroblastoma SY5Y lysate treated with the serum from a newly diagnosed patient with neuroblastoma. An aliquot of SY5Y proteins was solubilized in a urea cocktail and 40 micrograms of solubilized protein was loaded onto a carrier ampholyte base (pH 3.8) tube gel and separated in the first dimension for 12, 000 volt hours. The first- dimension tube gel was loaded onto a cassette containing the second dimension gel, after an equilibration step. Electrophoresis in the second dimension was performed until the tracking dye present in the equilibration buffer reached the opposite end of the second dimension gel, in relation to the first dimension gel. Following electrophoresis, the separated proteins were transferred on to a polyvinylideme flouride (PVDF) membrane. The membrane was preincubated with a blocking buffer and subsequently incubated with serum obtained from the same patient with neuroblastoma whose tumor was analyzed. The serum was utilized at a dilution of 1 : 100, for 1 hr at room temperature. After three washes with a buffer solution, the membrane was incubated for 1 hr with a rabbit anti-human IgG antibody. Reactive proteins were revealed with luminol. A set of coalesced protein spots labeled as LP1 was identified as containing β-tubulin isoforms for which an antibody was present in the patient's serum. This set was not detectable in a similar blot which was incubated with the serum of patients with other types of cancer or with the serum of normal individuals.
Figure 3. Western blot of two-dimensional gel separation of neuroblastoma protein lysate treated with the serum of a newly diagnosed patient with Wilms tumor. The conditions for the Western blot are as described in Figure 2. There is a lack of reactivity in the region of LP1.
Figure 4. Western blot of two-dimensional gel separation of SY5Y protein lysate treated with the serum of a newly diagnosed patient with neuroblastoma. The conditions for the Western Blot are as described in Figure 2 with the exception that the membranes were incubated for 1 hr with a rabbit anti-human IgM antibody. Reactive proteins were revealed with luminol. A set of lower molecular weight proteins indicated as Tl, T2 and T3 were identified as containing β- tubulin isoforms. This set was not detectable in a similar blot which was incubated with control sera. Figure 5. Western blot of SY5Y proteins treated with a monoclonal antibody that reacts with β-tubulin BI and BII. Reactive spots are identified as LP1 , and T1-T3.
Figure 6. Western blot of Sy5Y proteins treated with a monoclonal antibody that reacts with tubulin Bill. Reactive spots are identified as LP1, and TITS. Figure 7. Coomassie Blue stained blot of Sy5Y proteins. Similar blots were used to cut out LP1 spots for amino acid sequencing.
5. DETAILED DESCRIPTION OF THE INVENTION The present invention achieves a highly desirable objective, namely the identification of novel protein antigens for which individuals with, or at risk for different types of cancer, carry autoantibodies against tumor cell protein antigens. Such protein antigens can in turn be purified and utilized to screen a patient's serum for the presence of circulating antibodies to such antigens, by means of sensitive and rapid immunoadsorbent assays or by other procedures. The invention also relates to using the novel protein antigens to immunize patients suffering from diseases characterized by the expression of the identified protein antigens. Stimulation of an immunological response to such antigens, is intended to elicit a more effective attack of tumor cells; such as inter alia inhibiting tumor cell growth or facilitating the killing of tumor cells. Specifically, the method for identifying novel protein antigens, to which a subject with cancer produces autoantibodies, comprises the following steps:
(a) extracting proteins from a sample of cells;
(b) separating the extracted proteins by two-dimensional electrophoresis; (c) transferring the proteins separated by two-dimensional electrophoresis to a membrane;
(d) incubating the membrane with antiserum from a subject known to have the cancer;
(e) detecting the proteins to which autoantibodies in the patients serum have bound; and
(f) comparing the proteins to which antibodies in the subject's serum sample bind, to the proteins to which antibodies in a control serum sample bind, wherein those proteins bound by antibodies in the subject's serum but not the control serum are identified as proteins to which a subject with cancer produces autoantibodies.
A wide variety of protein mixtures that may contain antigens against which autoantibodies are present in serum can be prepared and separated into individual proteins by means of two-dimensional electrophoresis. Whole cell extracts or body fluids can be analyzed for proteins which have elicited autoantibodies. Alternatively, subsets of proteins such as secreted proteins, nuclear proteins or membrane proteins can be subjected to two-dimensional electrophoresis and analyzed separately for proteins which have elicited autoantibodies so as to increase the abundance of such proteins in the mixture. Preparative loads consisting of several milligrams of proteins in a mixture can also be applied to electrophoretic gels to increase the amounts of proteins which have elicited autoantibodies.
The particular advantage of the present invention is that no prior knowledge concerning the nature of the antigen is necessary. Autoantibodies to multiple antigens can be detected simultaneously through the use of a two- dimensional separation procedure. Additionally, the pattern of reactivity of a serum with a particular set of proteins in the two dimensional gel patterns, may be diagnostic of a particular cancer or indicative of a risk for a particular cancer.
The present invention is based on the discovery that serum from an individual that contains autoantibodies, such as a patient with cancer of the lung or neuroblastoma, can be used to identity protein antigens expressed in cells of a particular tissue, such as for example, cells of a tumor, or in a representative cell type, to which the patient has autoantibodies. As described herein, serum from neuroblastoma patients contained antibodies which were immunospecific for β- tubulin isoforms. 5.1. IDENTIFICATION OF DISEASE ASSOCIATED PROTETN ANTIGENS
The present invention provides a method for identifying cellular protein antigens to which patients with cancer may develop autoantibodies. The method is validated by the use of serum from individuals with cancer and from controls, without cancer. A body fluid which may contain autoantibodies, such as serum, is obtained from a patient known to have a particular cancer. A similar body fluid containing antibodies is obtained from a control subject that does not have cancer. In addition, tumor tissue as well as normal tissue to be used as a control is obtained. Additionally or alternatively, tumor tissues from other patients with the same disease and control tissues from other normal controls can be utilized. It is also not necessary to utilize primary tissues; cells grown in culture may provide appropriate substitutes for tumor tissues or controls. In addition, protein subsets from such tissues or such cells in culture may be prepared. Such subsets may include secreted proteins, nuclear proteins, membrane proteins or other subcellular fractions.
Two dimensional gel electrophoresis is used to separate proteins in complex mixtures of proteins. Electrophoresis in the first dimension generally separates proteins based on charge, while electrophoresis in the second dimension, referred to as SDS PAGE, separates proteins based on size
Prior to two-dimensional gel electrophoresis, aliquots of whole tissues, or cells are solubilized using any one of a variety of solubilization cocktails known to those of skill in the art. For example, tissue can be solubilized by addition of lysis buffer consisting of (per liter) 8 M urea, 20 ml of Nonidet P-40 surfactant, 20 ml of ampholytes (pH 3.5-10), 20 ml of 2-mercaptoethanol, and 0.2 mM of phenylmethylsulfonyl fluoride (PMSF) in distilled deionized water.
Because isoelectric focusing is sensitive to charge modification, it is important to minimize protein alterations (e.g., proteolysis, deamidation of glutamine and asparagine, oxidation of cystine to cystic acid, carbamylation) that can result from improper sample preparation. Thus, once solubilized, samples should be stored frozen at -80°C for short periods (<1 month) to limit significant protein modification. Approximately 30 μl aliquots containing 70 ug of protein may be loaded on individual gels. Prepared protein samples are loaded onto electrophoretic gels for isoelectric focusing separation in the first dimension which separates proteins based on charge. A number of first dimension gel preparations may be utilized including tube gels for carrier ampholyte-based separations, or gel strips for immobilized gradient based separations. After first dimension separation, proteins are transferred onto the second dimension gel, following an equilibration procedure and separated using SDS PAGE which separates proteins based on molecular weight. Multiple gels can be prepared from individual samples. Methods of two dimensional electrophoresis are known to those skilled in the art. For example, carrier ampholyte based two dimensional gel electrophoresis can be done as previously described (Strahier et al, Journal of Clinical Investigtion, 85:200-207, 1990). In most cases aliquots are immediately applied onto isoelectric focusing gels (IEF). First-dimension gels contain 50 ml of ampholytes per liter (pH 3.5-10). Generally, isoelectric focusing is done at 1,200 V for 10 h and 1,500 V for the last 2 h. 20 gels are generally run simultaneously. For the second-dimension separation by SDS PAGE, an acrylamide gradient of 1 1.4-14.0 g/ml can be used. If desired, protein spots in gels may be visualized by the silver-staining technique of Merril et al. (Merril et al, Science, 211 :1437-1438, 1961). Alternatively, immobilized pH gradient (IPG) two dimensional gels may be used (Hanash S. M., et al., 1991 , Proc. Natl. Acad. Sci., USA 88:5709-5713). Samples are prepared using lysis buffer as discussed above. For first dimension separation an immobilized pH gradient covering the separation range of pH 4-10 is used. The second dimension is the same as for the carrier ampholyte gels described above. IPG gels are prepared using derivatives of acrylamide having carboxyl or tertiary amino groups with specific pK values. A linear pH gradient is prepared from a dense, acidic solution and a light, basic solution using a two-chamber microgradient former. The pH gradient is stabilized during polymerization of the Immobiline acrylamide-bisacrylamide matrix by a co-linear gradient of glycerol. Formulations of buffering Immobiline mixtures with titrating Immobiline for the pH limit solutions for narrow pH gradients (1 pH unit) or for broad pH gradients (>1 pH unit, up to 6 pH units) have been published (Gianazza et al, Electrophoresis 6:113 (1985) and LKB application Note 324 (1984)).
The second dimension separates proteins on the basis of molecular weight in an SDS gel. An 11.5 to 14% (2.6% cross-linking) acrylamide gradient provides effective separation of proteins having a mass of from 10,000 to 100,000 Da. Proteins outside this range may be less well resolved. Proteins with molecular weight less than 10,000 Da electrophorese close to the dye front and are less well resolved.
Following separation, the proteins are transferred from the two dimensional gels onto membranes commonly used for Western blotting. The techniques of Western blotting and subsequent visualization of proteins are also well known in the art (Sambrook et al, "Molecular Cloning, A Laboratory Manual", 2nd Edition, Volume 3, 1989, Cold Spring Harbor). The standard procedures may be used, or the procedures may be modified as known in the art for identification of proteins of particular types, such as highly basic or acidic, or lipid soluble, etc. (See for example, Ausubel, et al., 1989, Current Protocols in Molecular Biology, Green
Publishing Associates and Wiley Interscience, N.Y.). The patient and control sera are diluted to various concentrations, e.g., one volume of serum to 100 volumes of buffer, prior to being utilized in an incubation step, as in the procedure of Western blot analysis. Non-specific binding may be minimized by preclearing the serum prior to the incubation step. A second antibody specific for the first antibody is utilized in the procedure of Western blot analysis to visualize proteins that reacted with the first antibody.
It is expected that some proteins will be visualized as spots as a result of nonspecific reactivity with antibodies in the serum. Spots corresponding to proteins that have elicited specific autoantibodies are distinguishable from nonspecific spots based on their presence in Western Blots prepared with patients' sera compared to control sera, and/or the presence of a spot in the disease tissues or cell lines or extracts compared to control tissues, cell lines or extracts.
The protein spots, in two dimensional gels of the same protein source used for Western blots are visualized using a staining procedure or by autoradiography. Spots in the gels that match the spots of interest in Western blots are identified by means of an overlay or a matching procedure between the gels and the blots. Once the spots that contain proteins that may have elicited autoantibodies are identified in two-dimensional gels, the protein can be extracted from the two- dimensional gels and utilized for a structural characterization and/or for making antibodies against such protein. The amino acid sequence of the protein can be derived by direct sequencing with an automated amino acid sequencer.
Once a protein of interest has been identified, it may be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any standard technique for purification of proteins. Such purified protein can be used in immunoassays designed to detect the presence of autoantibodies in a subject's serum, or alternatively, such protein preparations may be used for immunization as described infra. The present invention is demonstrated by way of example wherein elevated levels of circulating autoantibodies reactive against several specific β-tubulin isoforms and their cleavage products were detected in the sera of neuroblastoma patients. The detection and/or quantitative measurement of β-tubulin isoforms or their cleavage products in serum or other body fluids can be used in screening of subjects who are at risk for neuroblastoma or other disorders in which β-tubulin isoforms are expressed. Additionally, autoantibodies to the specific β-tubulin isoforms were not detected in neuroblastoma patients being treated, or in remission from the disease, indicating that measurement of autoantibodies can be used prognostically to stage the progression of the disease. Thus, the specific subtypes of tubulin autoantibodies may have diagnostic, prognostic, or therapeutic significance.
5.2. IMMUNOASSAYS In accordance with the invention, measurement of autoantibodies reactive against an identified tumor specific protein antigen can be used for the early diagnosis of diseases such as cancer. Moreover, the monitoring of autoantibody levels can be used prognostically to stage the progression of the disease. The detection of autoantibodies in a sample from a patient can be accomplished by any of a number of methods. Such methods include immunoassays which include but are not limited to competitive and non-competitive assay systems using techniques such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.
Such an immunoassay is carried out by a method comprising contacting a serum sample derived from a subject with a sample containing the protein antigen under conditions such that specific antigen-antibody binding can occur, and detecting or measuring the amount of any immunospecific binding by the autoantibody. In a specific aspect, such binding of autoantibody by tissue sections, for example, can be used to detect the presence of autoantibody wherein the detection of autoantibody is an indication of a diseased condition. The levels of autoantibodies in a sample are compared to the levels present in an analogous sample from a portion of the body or from a subject not having the disorder.
The immunoassays of the invention are not limited to those designed for detection of autoantibodies in a subject's serum, but also include, immunoassays for detecting expression of the identified protein antigens in a subject's sample. To this end, purified protein antigen can be used to produce antibodies that can be used in accordance with the invention. For example, the protein antigens identified by the method of the invention can be prepared in preparative gels, eluted from the gels, and used as immunogens for the production of antibodies which immunospecifically bind such an immunogen. The antibodies are made by methods known to those skilled in the art. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.
Antibodies can be used in assays, such as the immunoassays listed above, to detect, prognose, diagnose, or monitor cancer in an individual, or monitor the treatment thereof. In particular, such an immunoassay is carried out by a method comprising contacting a sample derived from a subject with an antibody under conditions such that immunospecific binding can occur, and detecting or measuring the amount of any immunospecific binding by the antibody In addition, reagents other than antibodies, such as, for example, nucleic acid molecules, polypeptides or chemical compounds that specifically bind to β-tubuhn isoforms, can be used m assays to detect the expression of β-tubulm isoforms
In a specific aspect, such binding of antibody by tissue sections, can be used to detect expression of the protein wherein the expression of the protein is an indication of a diseased condition The levels of expressed proteins are compared to levels relative to that present in an analogous sample from a portion of the body oi from a subject not having the disorder
5 3 IMMUNIZATION The identification of autoantibodies to novel protein antigens associated with particular cancers provides a basis for immunotherapy of the disease The patient may be immunized with the protein antigens to elicit an immune response which facilitates killing of tumor cells or inhibiting tumor cell growth The protein antigens can be prepared using the methods described above for purification of proteins
In an embodiment of the invention an immunogen comprising a purified protein antigen to which a patient cancer has developed autoantibodies, is used to elicit an immune response For administration, the protein antigen may be formulated with a suitable adjuvant in order to enhance the immunological response to the protein antigen Suitable adjuvants include, but are not limited to mineral gels, e g aluminum hydroxide, surface active substances such as lysolecithm, pluromc polyols, polyamons, peptides, oil emulsions, and potentially useful human adjuvants such as BCG (bacilli Calmett-Guerin) and (Corynebacterium parvum) Many methods may be used to introduce the formulations derived above, including but not limited to oral, mtradermal, intramuscular, mtrapeπtoneal, intravenous, and subutaneous The results presented in the Examples infra are discussed below In particular, the data presented m Section 7 demonstrate that specific β-tubuhn isoforms are expressed in the tumors of subjects having neuroblastoma. Knowledge of the antigenic nature of β-tubulin isoforms in cancer can be used in devising therapeutic strategies in the form of immunotherapy directed against cancer using β-tubulin isoforms or peptides as an intermediate target to stimulate an immune response against the tumor or in the form of gene therapy using genes that encode all or part of β-tubulin isoforms as an intermediate target. Additionally, β-tubulin III differs from other forms of tubulin by a short sequence at the C-terminal end. Thus peptides encompassing this sequence may be utilized as an immunogen to elicit antibodies specifically reactive to against tumors that express β-tubulin III.
6. EXAMPLE: DETECTION OF A TUMOR SPECIFIC
ANTIGEN USING SERUM ISOLATED FROM A PATIENT HAVING CANCER
The method of the present invention was applied to patients with lung cancer for identification of tumor specific antigens. One such experiment is described below. An aliquot of a lung adenocarcinoma tumor was solubilized in a urea cocktail, as described above, and 40 micrograms of solubilized protein was loaded onto a carrier ampholyte based (pH 3-8) tube gel and subjected to isoelectric focusing in the first dimension for 12,000 volt hours (700V x 16h and 1000V x 2h). The first- dimension tube gel was loaded onto a cassette containing the second dimension gel, after an equilibration step. Electrophoresis in the second dimension using SDS PAGE, was done until the tracking dye present in the equilibration buffer reached the opposite end of the second dimension gel, in relation to the first dimension gel. Following electrophoresis the separated proteins were transferred onto a nitrocellulose membrane. The membrane was preincubated with a blocking buffer and subsequently incubated with serum obtained from a patient with lung adenocarcinoma at a dilution of 1/100 (diluted in Tris-buffered-saline (TBS) ;0.01% Tween 20; 1.8 gm/100 ml nonfat dry milk), for 1 hr at room temperature. After three washes with a buffer solution, the membrane was incubated for 1 hr with a sheep anti-human antibody (available from Amersham). Reactive proteins were revealed with luminol. A candidate protein in the tumor for which an antibody was present in the patient's serum is shown in Figure 1A. As indicated in Figure IB, the protein spot was not detectable in a blot of normal lung proteins which was incubated with the patient's serum.
7. EXAMPLE: DETECTION OF ANTIBODIES SPECIFIC FOR β-TUBULIN
ISOFORMS IN THE SERA OF SUBJECTS WITH NEUROBLASTOMA
Using the method of the present invention, sera from subjects with neuroblastoma were screened for reactivity against tumor proteins. The sera samples from the neuroblastoma patients were found to be reactive against a set of neuroblastoma specific proteins identified as β-tubulin isoforms and their cleavage products.
7.1. MATERIALS AND METHODS Sera were obtained from patients with neuroblastoma as well as from patients with other tumor types including cancer of the lung, esophagus, sarcomas and Wilms tumors. Different Western blots were prepared using the different tumors or the neuroblastoma cell line SY5Y as sources for solubilized proteins. An aliquot of SY5Y proteins was solubilized in a urea cocktail as described above and 40 micrograms of solubilized protein was loaded onto a carrier ampholyted base (pH 3.8) tube gel and separated by isoelectric focusing in the first dimension for 12, 000 volt hours (700V x 16 h followed by 1000V x 2 h) . The first-dimension tube gel was loaded onto a cassette containing the second dimension gel, after an equilibration step. Electrophoresis in the second dimension using SDS PAGE was done until the tracking dye present in the equilibration buffer reached the opposite end of the second dimension gel, in relation to the first dimension gel. Following electrophoresis the separated proteins were transferred on to a polyvinylideme flouride (PVDF) membrane (Millipore). The membrane was preincubated with a blocking buffer and subsequently incubated with serum obtained from the same patient with neuroblastoma whose tumor was being analyzed. The serum, which was diluted 1 :100 in the buffer solution (Tris-buffered-saline containing .01% Tween20 and 1.8 gm/100 ml non-fat dry milk), was incubated with the filter for 1 hr at room temperature. After three washes with the buffer solution, the membrane was incubated for 1 hr with a rabbit anti-human IgG antibody (available from Amersham). Reactive proteins were revealed with luminol. A set of coalesced protein spots labeled LPl, were identified as containing β-tubulin isoforms for which an autoantibody was present in the patient's serum.
Several immunoreactive spots occurred in Western blots of neuroblastoma patient sera. These spots were absent in Western blots of other tumors or in Western blots of neuroblastoma tumors that were treated with control sera
(Figures 2 and 3). The set of neighboring immunoreactive proteins, designated LPl, observed in blots in which the second antibody was directed against IgG or IgM (Figures 2 and 3, respectively) was identified in two-dimensional separations of the same tumor extracts, in which total proteins were visualized by staining with silver or Coomassie blue, based on their isoelectric point (pi) and MW following a matching process (Figure 5). This protein constellation was identified as containing tubulin β- isoforms types I, II and III as determined by amino acid sequencing and reactivity with known antibodies to these tubulin β-isoforms.
For amino acid sequencing, several blots of neuroblastoma tumor proteins were prepared and stained with Coomasie Blue. The coalesced spots, designated LPl, which occurred in the position of the immunoreactive constellation of spots were excised from four contiguous areas of neuroblastoma blots stained with Coomassie Blue and the N-terminal amino acid sequence was determined for each excised protein spot. The N-terminal amino acid sequences were compared to the known N-terminal sequences of the β-tubulin isoforms .
The reported N-terminal sequences for the β-tubulin isoforms are as follows:
M.W. P.I.
TBB1 MREIVHIQAGQCGNQI 49759 4.75 (SEQ ID NOT) TBB3 MREIVHIQAGQCGNQI 50517 4.86 (SEQ ID NOT)
TBB2 MREIVHLQAGQCGNQI 49831 4.79 (SEQ ID NO:2) TBB5 MREIVHLQAGQCGNQI 49631 4.81 (SEQ ID NO:2)
TBA1 MRECISIHVGQAGVQI 50157 5.02 (SEQ ID NO:3)
TBA4 MRECISVHVGQAGVQM 49924 4.95 (SEQ ID NO:4)
The spots designated LPl a to LPld in Figure 7 were excised and the amino terminal sequence of each protein was determined. The amino acid sequences were as follows: I. LPla major- MREIVHIQAGQCGNQI (SEQ ID NOT) minor- EEGCVSLQVGQAGVQI (SEQ ID NO:5)
The major sequence of LPl is that of tubulin isoform TBBl or TBB3, the minor is TBB2 or TBB5. TBBl and TBB3 have the same N-terminus, but differ at C -terminus. There were some minor signals as well in some cycles. TBB2 and TBB5 have L instead of I in position 7. There was some L observed in this cycle. However it may have come from an unrelated sequence along with the other minor residues.
II. LPlb major- MRECISIHVGQAGVQI (SEQ ID NO:3) minor- MRLIVHAHAGQAGNQI (SEQ ID NO:6) minor- MRLIVDAHAGQAGNQI (SEQ ID NO:7)
The major sequence is of LPlb is that of tubulin isoform TBA1 and the minor sequence is that of tubulin isoform TBBl and/or TBB3.
III. LPlc major- MREIVHIQAGQCGNQI (SEQ ID NOT) minor- MREIVHLQAGQCGNQI (SEQ ID NO:2)
The major sequence of LPlc is that of tubulin isoform TBBl and/or TBB3 with possibly some TBB5 and/or TBB2 tubulin isoforms present (Lin #7). IV. LPld major- MREIVSIHVGQA (SEQ ID NO: 8) minor- MREXaalHIXaaAGQXaa (SEQ ID NO:9), wherein the first Xaa refers to the presence of a C or T residue; the second Xaa refers to the presence of a Q or P residue; and the third Xaa refers to the presence of a C residue.
The major sequence of LPld is tubulin isoform TBBl and/or TBB3 with a minor amount of TBAltubulin isoform detected. β-tubulin isoforms types I and II and type III were found to be expressed at high level in neuroblastoma tumors and the SY5Y based on Western blot analysis of neuroblastoma tumor proteins separated by two dimensional gel electrophoresis, using isoform specific tubulin beta antibodies (Figure 5, 6).
Another set of immunoreactive proteins observed in Western blots of neuroblastoma tumors and Sy5Y cell line, in which the second antibody was directed against IgM were identified as cleavage products of β-tubulin isoforms, based on their reactivity with β-tubulin isoform specific antibodies (Figure 4). This set of neighboring proteins was also identified in two-dimensional separations of the same tumor extracts, in which proteins were visualized by staining with silver or Coomassie blue, based on their isoelectric point (pi) and molecular weight (MW) following a matching process (Figure 7). Cleavage products of tubulin beta isoforms types I and II and type III were found to be expressed at high level in neuroblastoma tumors based on Western blot analysis of neuroblastoma tumor and SY5Y proteins separated by two dimensional gel electrophoresis using isoform specific tubulin beta antibodies ( Figures 4, 5 and 6).
7.2. RESULTS
For identification of neuroblastoma protein antigens and the presence of serum autoantibodies to neuroblastoma tumor proteins, sera from patients with neuroblastoma was used to screen for reactivity against tumor proteins separated by the technique of high resolution two-dimensional electrophoresis. Tumor proteins were transferred following their two-dimensional separation onto a polyvinylideme flouride (PVDF) membrane and incubated with serum from newly diagnosed patients with neuroblastoma using the technique of Western blotting (Figures 2 and 4). Sera from patients with other types of cancer and from normal individuals were similarly utilized as controls (Figure 3). Proteins which reacted with antibodies present in serum were detected based on the visualization of a spot following incubation with a second antibody directed against the first antibody. Antibody specificity was determined by means of comparisons of Western blots of different tumor types reacted with different neuroblastoma patient sera, with Western blots reacted with control sera. Several immunoreactive spots that were found in Western blots of neuroblastoma tumors and a neuroblastoma cell line that were incubated with sera from neuroblastoma patients were absent in Western blots of other tumors or in neuroblastoma Western blots that were treated with control sera. One set of neuroblastoma immunoreactive proteins was localized in two-dimensional separations of neuroblastoma proteins in which proteins were revealed by staining with silver or Coomassie Blue. Localization was based on a matching process which took into account protein isoelectric point (pi) and molecular weight. Following elution from the membrane, he immunoreactive set of protein antigens were identified as β-tubulin isoforms as determined by amino acid sequencing, mass spectrometry and reactivity with known antibodies to tubulin beta isoforms. β-tubulin isoforms were found to be expressed at high level in neuroblastoma tumors based on Western blot analysis of neuroblastoma tumor proteins separated by two dimensional gel electrophoresis, which were reacted with isoform specific β-tubulin antibodies. Another set of immunoreactive proteins were similarly identified as cleavage products of tubulin beta isoforms. Thus, patients with neuroblastoma appear to make autoantibodies to β- tubulin isoforms or to their cleavage products. Interestingly, serum taken from neuroblastoma patients either in remission or being treated for their disease fail to contain autoantibodies reactive against β-tubulins. The identification of tubulin beta isoforms as immunogenic in cancer provides a basis for the development of diagnostic and screening tests for cancers in which these isoforms are expressed and for the development of novel tubulin based strategies for cancer therapy. Once proteins that have elicited autoantibodies are identified, it becomes possible to produce them in large quantities through recombinant DNA technology or other enrichment or purification procedures. Specific antibodies and antisera can be produced against these proteins or against synthetic peptides which match the derived sequence of the protein(s) of interest.
The present invention is not to be limited in scope by the embodiments disclosed in the examples which are intended as an illustration of one aspect of the invention, and any compositions or methods which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the claims.
SEQUENCE LISTING
(1) GENERAL INFORMATION
(I) APPLICANT: University of Michigan
(ii) TITLE OF THE INVENTION: METHOD FOR IDENTIFICATION OF CELLULAR PROTEIN ANTIGENS AND PRESENCE OF
ANTIBODIES TO SPECIFIC CELLULAR ANTIGENS IN SERUM
(in) NUMBER OF SEQUENCES: 9
(iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Baker & Botts, L.L.P.
(B) STREET: 30 Rockefeller Plaza
(C) CITY: New York
(D) STATE: NY
(E) COUNTRY: U.S.A. (F) ZIP: 10112
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS (D) SOFTWARE: FastSEQ Version 2.0
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 26-JUN-1998
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Seide, Rochelle K
(B) REGISTRATION NUMBER: 32,300
(C) REFERENCE/DOCKET NUMBER: 31755-PCT
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 212-705-5000
(B) TELEFAX: 212-705-5020
(C) TELEX:
(2) INFORMATION FOR SEQ ID NO : 1 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: None
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1 :
Met Arg Glu He Val His He Gin Ala Gly Gin Cys Gly Asn Gin He 1 5 10 15
(2) INFORMATION FOR SEQ ID NO : 2 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 :
Met Arg Glu He Val His Leu Gin Ala Gly Gin Cys Gly Asn Gin He 1 5 10 15
(2) INFORMATION FOR SEQ ID NO : 3 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: None
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3 :
Met Arg Glu Cys He Ser He His Val Gly Gin Ala Gly Val Gin He 1 5 10 15
(2) INFORMATION FOR SEQ ID NO : 4 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: None
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 4 :
Met Arg Glu Cys He Ser Val His Val Gly Gin Ala Gly Val Gin Met 1 5 10 15
(2) INFORMATION FOR SEQ ID NO : 5 : (l) SEQUENCE CHARACTERISTICS
(A) LENGTH 16 ammo acids
Figure imgf000026_0001
(C) STRANDEDNESS single (D) TOPOLOGY linear
(ii) MOLECULE TYPE None
(xi) SEQUENCE DESCRIPTION SEQ ID NO 5
Glu Glu Gly Cys Val Ser Leu Gin Val Gly Gin Ala Gly Val Gin He 1 5 10 15
(2) INFORMATION FOR SEQ ID NO 6
(l) SEQUENCE CHARACTERISTICS
(A) LENGTH 16 ammo acids
Figure imgf000026_0002
(C) STRANDEDNESS single (D) TOPOLOGY linear
(ii) MOLECULE TYPE None
(xi) SEQUENCE DESCRIPTION SEQ ID NO 6
Met Arg Leu He Val His Ala His Ala Gly Gin Ala Gly Asn Gin He 1 5 10 15
(2) INFORMATION FOR SEQ ID NO 7
(l) SEQUENCE CHARACTERISTICS
(A) LENGTH 16 ammo acids
Figure imgf000026_0003
(C) STRANDEDNESS single (D) TOPOLOGY linear
(ii) MOLECULE TYPE None (xi) SEQUENCE DESCRIPTION SEQ ID NO 7
Met Arg Leu He Val Asp Ala Hi s Ala Gly Gin Ala Gly Asn Gin He 1 5 10 15
(2) INFORMATION FOR SEQ ID NO 8
(l) SEQUENCE CHARACTERISTICS
(A) LENGTH 12 ammo acids
Figure imgf000027_0001
(C) STRANDEDNESS Single
(D) TOPOLOGY linear
(n) MOLECULE TYPE None
(xi) SEQUENCE DESCRIPTION SEQ ID NO 8
Met Arg Glu He Val Ser He His Val Gly Gin Ala 1 5 10
(2) INFORMATION FOR SEQ ID NO 9
(l) SEQUENCE CHARACTERISTICS
(A) LENGTH 12 ammo acids
(B) TYPE ammo acid
(C) STRANDEDNESS single
(D) TOPOLOGY linear
(n) MOLECULE TYPE None
(xi) SEQUENCE DESCRIPTION SEQ ID NO 9
Met Arg Glu Xaa He His He Xaa Ala Gly Gin Xaa 1 5 10

Claims

1. A method for identifying proteins, to which a subject with cancer produces autoantibodies, said method comprising: (a) extracting proteins from a sample of cells; (b) separating the extracted proteins by two-dimensional electrophoresis;
(c) transferring the proteins separated by two-dimensional electrophoresis to a membrane;
(d) incubating the membrane with antiserum from a subject known to have the cancer;
(e) detecting the proteins to which autoantibodies in the patients serum have bound; and
(f) comparing the proteins to which antibodies in the subject's serum sample bind to proteins to which antibodies in control serum sample bind, wherein those proteins bound by antibodies in the subject's serum but not the control serum are identified as proteins to which a subject with cancer produces autoantibodies.
2 The method of Claim 1 wherein the sample of cells is derived from the subject's tumor.
3. The method of Claim 1 wherein the sample of cells is derived from a continuous cell line representative of the subject's tumor.
4. The method of Claim 1 wherein the step of detecting the proteins to which autoantibodies in the subject's serum sample have bound comprises the use of a signal-generating component bound to an antibody that is specific for antibodies in the subject's sample.
5. A method for diagnosis and prognosis of cancer in a subject, comprising:
(a) obtaining a serum sample from a subject; and (b) detecting the presence of autoantibodies specific for a protein identified using the method of Claim 1, wherein the presence of autoantibodies indicates the presence of cancer.
6. A method for diagnosis and prognosis of cancer in a subject, comprising:
(a) obtaining a serum sample from a subject; and
(b) detecting the presence of autoantibodies specific for a ╬▓-tubulin isoform, wherein the presence of autoantibodies specific for a ╬▓-tubulin isoform indicates the presence of cancer.
7. The method of Claim 7 wherein the subject is a neuroblastoma patient.
8. The method of Claim 7 wherein the presence of autoantibodies in the sample is measured by an immunoassay comprising:
(a) immobilizing a protein identified using the method of Claim 1 onto a membrane or substrate;
(b) contacting the membrane or substrate with a subject's serum sample; and
(c) detecting the presence of autoantibodies specific for the protein in the subject's serum sample, wherein the presence of autoantibodies indicates the presence of cancer.
. The method of Claim 8 wherein the immobilized protein is a ╬▓-tubulin isoform.
10. A method for diagnosis for the presence of cancer in a subject comprising, detecting in a sample of cells derived from said subject the expression of a protein identified using the method of Claim 1.
11. The method of Claim 10 wherein the expression of the protein identified using the method of Claim 1 is detected using an immunoassay.
12. The method of Claim 1 1 wherein the immunoassay is an in situ hybridization assay.
13. The method of Claim 11 wherein the immunoassay is an immunoprecipitation assay.
14. The method of Claim 11 wherein the protein is a ╬▓-tubulin isoform.
15. A method for stimulating in a subject an immune response specific for a protein identified using the method of Claim 1, comprising administering to said subject a composition containing said protein, in an amount sufficient to elicit an immune response.
16. A method for stimulating in a subject an immune response specific for a protein identified using the method of Claim 1, comprising administering to said subject cells from the immune system derived from said subject.
17. The method of Claim 1 wherein the protein is a ╬▓-tubulin isoform.
18. A composition comprising a protein identified using the method of Claim 1 and an acceptable carrier.
19. A composition containing an antibody that immunospecifically binds to a protein identified using the method of Claim 1.
> 20. The composition of Claim 18 wherein the antibody is conjugated to a signal-generating compound.
21. The composition of Claim 18 wherein the antibody is conjugated to a cytotoxic reagent.
PCT/US1998/013295 1997-06-26 1998-06-26 Method for identification of tumor antigens with autoantibodies in serum WO1999000671A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU82673/98A AU8267398A (en) 1997-06-26 1998-06-26 Method for identification of tumor antigens with autoantibodies in serum
DE69823660T DE69823660D1 (en) 1997-06-26 1998-06-26 METHOD FOR IDENTIFYING TUMORANTIGENS WITH AUTOANTIBODIES IN SERUM
JP54639598A JP4065574B2 (en) 1997-06-26 1998-06-26 Methods for identifying the presence of antibodies against intracellular protein antigens and specific intracellular protein antigens in serum
EP98932884A EP0991945B2 (en) 1997-06-26 1998-06-26 Method for identification of tumor antigens with autoantibodies in serum
CA002294514A CA2294514C (en) 1997-06-26 1998-06-26 Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum
AT98932884T ATE266203T1 (en) 1997-06-26 1998-06-26 METHOD FOR IDENTIFYING TUMOR ANTIGENS WITH AUTOANTIBODIES IN SERUM
DK98932884T DK0991945T4 (en) 1997-06-26 1998-06-26 Method for identifying tumor antigens with serum autoantibodies
US09/464,840 US6677128B1 (en) 1997-06-26 1999-12-16 Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum
US10/674,228 US20040191841A1 (en) 1998-06-26 2003-09-29 Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5083297P 1997-06-26 1997-06-26
US60/050,832 1997-06-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/464,840 Continuation US6677128B1 (en) 1997-06-26 1999-12-16 Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum

Publications (2)

Publication Number Publication Date
WO1999000671A2 true WO1999000671A2 (en) 1999-01-07
WO1999000671A3 WO1999000671A3 (en) 1999-06-10

Family

ID=21967731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/013295 WO1999000671A2 (en) 1997-06-26 1998-06-26 Method for identification of tumor antigens with autoantibodies in serum

Country Status (9)

Country Link
EP (1) EP0991945B2 (en)
JP (2) JP4065574B2 (en)
AT (1) ATE266203T1 (en)
AU (1) AU8267398A (en)
CA (2) CA2665707C (en)
DE (1) DE69823660D1 (en)
DK (1) DK0991945T4 (en)
ES (1) ES2216295T5 (en)
WO (1) WO1999000671A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041612A1 (en) * 1998-02-13 1999-08-19 Oxford Glycosciences (Uk) Ltd. Methods and compositions for diagnosis of hepatoma
WO2001011372A1 (en) * 1999-08-06 2001-02-15 The Regents Of The University Of Michigan Annexins and autoantibodies used as markers for cancer
WO2001013122A2 (en) * 1999-08-18 2001-02-22 Tularik Inc. Method for monitoring beta tubulin isotype modification
DE10151051A1 (en) * 2001-09-14 2003-04-10 Reinhard Zeidler Method for identifying antigens, useful for raising antibodies or for loading antigen-presenting cells, from reaction of cell lysate with serum and separating immune complexes
WO2003064593A2 (en) * 2001-11-09 2003-08-07 Virginia Mason Research Center Antigen panels and methods of using the same
WO2004044590A1 (en) * 2002-11-14 2004-05-27 The University Of Nottingham Tumour marker proteins and uses thereof
WO2005001480A1 (en) * 2003-06-27 2005-01-06 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
US7214498B2 (en) 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
EP1952157A2 (en) * 2005-11-10 2008-08-06 University of Kentucky Lung cancer diagnostic assay
EP2041569A2 (en) * 2006-07-08 2009-04-01 University Of Kentucky Research Foundation Lung cancer diagnostic assay

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011107064A (en) * 2009-11-20 2011-06-02 Nitto Boseki Co Ltd Immunoassay method of autoantibody to clathrin heavy chain, kit used for the same, and cancer determination method using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018535A1 (en) * 1991-04-09 1992-10-29 Eastman Kodak Company Endometrial antigen, composition, test kit and method for endometrial antibody determination
WO1994028021A1 (en) * 1993-05-28 1994-12-08 Medical University Of South Carolina Endometrial proteins, antigenic compositions and methods for detecting endometriosis
US5405749A (en) * 1991-12-06 1995-04-11 Polans; Arthur S. Method for identifying and purifying a cancer associated retinopathy autoantigen, and testing patient serum for the autoantibody to the autoantigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018535A1 (en) * 1991-04-09 1992-10-29 Eastman Kodak Company Endometrial antigen, composition, test kit and method for endometrial antibody determination
US5405749A (en) * 1991-12-06 1995-04-11 Polans; Arthur S. Method for identifying and purifying a cancer associated retinopathy autoantigen, and testing patient serum for the autoantibody to the autoantigen
WO1994028021A1 (en) * 1993-05-28 1994-12-08 Medical University Of South Carolina Endometrial proteins, antigenic compositions and methods for detecting endometriosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BACHVAROFF, R.J. ET AL.: "Appearance of cytoskeletal components on the surface of leukemia cells and of lymphocytes transformed by mitogens and Epstein-Barr virus" PROC. NATL. ACAD. SCI. USA, vol. 77, no. 8, August 1980, pages 4979-4983, XP002098017 *
HANASH, S.M. ET AL.: "Two-dimensional electrophoresis with immobilized pH gradients in the first dimension Protein focusing as a function of time." ELECTROPHORESIS, vol. 8, 1987, pages 229-234, XP002098015 cited in the application *
RAXWORTHY, M.J. ET AL.: "An alteration in tubulin expression detected in SV40 transformed 3T3 cells" CELL BIOLOGY INTERNATIONAL REPORTS, vol. 10, no. 7, July 1986, pages 555-564, XP002098016 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041612A1 (en) * 1998-02-13 1999-08-19 Oxford Glycosciences (Uk) Ltd. Methods and compositions for diagnosis of hepatoma
WO2001011372A1 (en) * 1999-08-06 2001-02-15 The Regents Of The University Of Michigan Annexins and autoantibodies used as markers for cancer
US7955602B2 (en) 1999-08-06 2011-06-07 Regents Of The University Of Michigan Annexin proteins and autoantibodies as serum markers for cancer
US7759081B2 (en) 1999-08-06 2010-07-20 Regents Of The University Of Michigan Annexin proteins and autoantibodies as serum markers for cancer
EP1734368A3 (en) * 1999-08-06 2007-03-07 The Regents Of The University Of Michigan Annexins and autoantibodies used as markers for cancer
EP1734368A2 (en) * 1999-08-06 2006-12-20 The Regents Of The University Of Michigan Annexins and autoantibodies used as markers for cancer
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
WO2001013122A2 (en) * 1999-08-18 2001-02-22 Tularik Inc. Method for monitoring beta tubulin isotype modification
US6306615B1 (en) * 1999-08-19 2001-10-23 Tularik Inc. Detection method for monitoring β tubulin isotype specific modification
WO2001013122A3 (en) * 1999-08-19 2001-06-21 Tularik Inc Method for monitoring beta tubulin isotype modification
US7214498B2 (en) 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
DE10151051A1 (en) * 2001-09-14 2003-04-10 Reinhard Zeidler Method for identifying antigens, useful for raising antibodies or for loading antigen-presenting cells, from reaction of cell lysate with serum and separating immune complexes
DE10151051B4 (en) * 2001-09-14 2007-07-12 Zeidler, Reinhard, Dr. Identification of antigens by xenogeneic, allogenic or autologous antibody-mediated precipitation
WO2003064593A3 (en) * 2001-11-09 2004-02-05 Virginia Mason Res Ct Antigen panels and methods of using the same
WO2003064593A2 (en) * 2001-11-09 2003-08-07 Virginia Mason Research Center Antigen panels and methods of using the same
WO2004044590A1 (en) * 2002-11-14 2004-05-27 The University Of Nottingham Tumour marker proteins and uses thereof
WO2005001480A1 (en) * 2003-06-27 2005-01-06 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
EP1952157A4 (en) * 2005-11-10 2009-04-08 Univ Kentucky Res Found Lung cancer diagnostic assay
EP1952157A2 (en) * 2005-11-10 2008-08-06 University of Kentucky Lung cancer diagnostic assay
EP2041569A4 (en) * 2006-07-08 2009-11-18 Univ Kentucky Res Found Lung cancer diagnostic assay
EP2041569A2 (en) * 2006-07-08 2009-04-01 University Of Kentucky Research Foundation Lung cancer diagnostic assay

Also Published As

Publication number Publication date
JP4065574B2 (en) 2008-03-26
EP0991945B1 (en) 2004-05-06
EP0991945A2 (en) 2000-04-12
CA2665707A1 (en) 1999-01-07
CA2665707C (en) 2013-02-12
CA2294514A1 (en) 1999-01-07
ES2216295T3 (en) 2004-10-16
ES2216295T5 (en) 2008-06-01
DK0991945T4 (en) 2008-06-09
AU8267398A (en) 1999-01-19
WO1999000671A3 (en) 1999-06-10
CA2294514C (en) 2009-09-01
JP2007333744A (en) 2007-12-27
DE69823660D1 (en) 2004-06-09
JP2002508835A (en) 2002-03-19
DK0991945T3 (en) 2004-07-26
EP0991945B2 (en) 2008-02-20
ATE266203T1 (en) 2004-05-15

Similar Documents

Publication Publication Date Title
US7759081B2 (en) Annexin proteins and autoantibodies as serum markers for cancer
JP2007333744A (en) Method for identifying existence of antibody against intracellular protein antigen, and specific intracellular protein antigen within serum
US20020034773A1 (en) S100 proteins and autoantibodies as serum markers for cancer
US20040191841A1 (en) Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum
US6677128B1 (en) Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum
EP1796723B1 (en) Method of diagnosing cancer by detecting the expression of spag9 or the presence of anti-spag9 antibodies
AU2005203709B2 (en) Method for identification of tumor antigens with autoantibodies in serum
AU3208997A (en) Protein markers for esophageal cancer
US20040005645A1 (en) Protein markers for esophageal cancer
AU2004201392B2 (en) S100 proteins and autoantibodies as serum markers for cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 82673/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09464840

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2294514

Country of ref document: CA

Ref country code: CA

Ref document number: 2294514

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998932884

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998932884

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1998932884

Country of ref document: EP